Utama › Kanser Paru-paru Bukan Sel Kecil › Illinois › Bloomington
Kajian klinikal Kanser Paru-paru Bukan Sel Kecil di Bloomington, IL
11 kajian untuk Kanser Paru-paru Bukan Sel Kecil sedang mencari peserta di lokasi dalam dan sekitar Bloomington (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Mengambil pesertaFasa 3
- Illinois CancerCare-Bloomington, Bloomington
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
Mengambil pesertaFasa 2
- OSF Saint Joseph Medical Center, Bloomington
- Illinois CancerCare-Bloomington, Bloomington
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
Mengambil pesertaFasa 3
- Illinois CancerCare-Bloomington, Bloomington
- Carle BroMenn Medical Center, Normal · 2 mi jauh
- Carle Cancer Institute Normal, Normal · 2 mi jauh
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Mengambil pesertaFasa 3
- Illinois CancerCare- Bloomington, Bloomington
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Mengambil pesertaFasa 3
- Illinois CancerCare - Bloomington, Bloomington
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Mengambil pesertaFasa 2
- Illinois CancerCare-Bloomington, Bloomington
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Mengambil pesertaFasa 2
- Illinois CancerCare-Bloomington, Bloomington
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Mengambil pesertaFasa 2
- Illinois CancerCare-Bloomington, Bloomington
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Mengambil pesertaFasa 2
- Illinois CancerCare-Bloomington, Bloomington
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Mengambil pesertaFasa 2/3
- Illinois CancerCare-Bloomington, Bloomington
- Carle BroMenn Medical Center, Normal · 2 mi jauh
- Carle Cancer Institute Normal, Normal · 2 mi jauh
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Mengambil pesertaKajian pemerhatian
- Illinois CancerCare-Bloomington, Bloomington
- Carle Cancer Institute Normal, Normal · 2 mi jauh
Kajian Kanser Paru-paru Bukan Sel Kecil di bandar lain
- Houston, TX145 kajian
- New York City, NY120 kajian
- Arlington, VA104 kajian
- Nashville, TN97 kajian
- Boston, MA90 kajian
- Los Angeles, CA87 kajian
- St. Louis, MO73 kajian
- Chicago, IL61 kajian
- Baltimore, MD60 kajian
- San Antonio, TX59 kajian
- Columbus, OH56 kajian
- Washington, DC55 kajian
Kajian lain di Bloomington
- Kanser Paru-paru9 kajian
- Kanser Prostat7 kajian
- Kanser Kolorektal7 kajian
- Karsinoma Sel Skuamosa Kepala dan Leher6 kajian
- Kanser Pankreas5 kajian
- Melanoma5 kajian
- Kanser Hipofaring5 kajian
- Kanser Laring5 kajian
- Kanser Oral5 kajian
- Kanser Payudara5 kajian
- Kanser Ginjal (Karsinoma Sel Renal)4 kajian
- Leukemia Mieloid Akut4 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.